Cargando…

Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials

The study compared immunogenicity and safety between alternative higher-dose and standard-dose trivalent vaccines in immunocompromised individuals. A literature search was performed using the PubMed, Embase, and Cochrane databases from inception until March 2019 to identify studies comparing the imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Jiun-Ji, Lin, Chin, Ho, Ching-Liang, Chen, Po-Huang, Lee, Cho-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571572/ https://www.ncbi.nlm.nih.gov/pubmed/31035712 http://dx.doi.org/10.3390/jcm8050590

Ejemplares similares

The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial
por: Young, Barnaby, et al.
Publicado: (2017)

996. A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in US Nursing Homes
por: Gravenstein, Stefan, et al.
Publicado: (2018)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
por: Nunes, Marta C, et al.
Publicado: (2020)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia
por: McManus, Meghann, et al.
Publicado: (2013)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

530 Disease Modulation in Older Adults Vaccinated with High-Dose Versus Standard-Dose Influenza Vaccine
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

989. Clinical Effectiveness of High-Dose Trivalent vs. Quadrivalent Influenza Vaccination Among Veterans Health Administration Patients
por: Young-Xu, Yinong, et al.
Publicado: (2018)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza
por: Bautista, Francisco, et al.
Publicado: (2019)

Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients
por: Talbot, H Keipp, et al.
Publicado: (2018)

Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial
por: Coleman, Brenda L, et al.
Publicado: (2015)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Influenza B vaccine lineage selection—An optimized trivalent vaccine
por: Mosterín Höpping, Ana, et al.
Publicado: (2016)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Acquired immune responses to the seasonal trivalent influenza vaccination in COPD
por: Staples, K. J., et al.
Publicado: (2019)

Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults
por: Chang, Kuo-Hsuan, et al.
Publicado: (2019)

Assessment of trivalent live influenza vaccines in MDCK cell line
por: Landgraf, G., et al.
Publicado: (2021)

6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
por: Pelton, Stephen I, et al.
Publicado: (2020)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial
por: Sullender, Wayne M, et al.
Publicado: (2019)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors
por: Becker, Debbie L., et al.
Publicado: (2016)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military
por: Gao, Dongqi, et al.
Publicado: (2016)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine
por: Demeulemeester, Marc, et al.
Publicado: (2016)

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
por: Levin, Myron J., et al.
Publicado: (2021)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial
por: Chang, Yu-Tzu, et al.
Publicado: (2021)

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ldm0abdfpbeiu9h0j2e60ou3d6